Department of Physiology and Biophysics , Virginia Commonwealth University School of Medicine , Richmond , Virginia 23298 , United States.
Department of Medicinal Chemistry , Virginia Commonwealth University School of Pharmacy , Richmond , Virginia 23298 , United States.
ACS Chem Neurosci. 2019 May 15;10(5):2318-2331. doi: 10.1021/acschemneuro.8b00637. Epub 2019 Jan 16.
Pharmacophore models for 5-HT receptor antagonists consist of two aromatic/hydrophobic regions at a given distance from a basic amine. We have previously shown that both aromatic/hydrophobic moieties are unnecessary for binding or antagonist action. Here, we deconstructed the 5-HT receptor antagonist/serotonin-dopamine antipsychotic agent risperidone into smaller structural segments that were tested for 5-HT receptor affinity and function. We show, again, that the entire risperidone structure is unnecessary for retention of affinity or antagonist action. Replacement of the 6-fluoro-3-(4-piperidinyl)-1,2-benz[ d]isoxazole moiety by isosteric tryptamines resulted in retention of affinity and antagonist action. Additionally, 3-(4-piperidinyl)-1,2-benz[ d]isoxazole (10), which represents less than half the structural features of risperidone, retains both affinity and antagonist actions. 5-HT receptor homology modeling/docking studies suggest that 10 binds in a manner similar to risperidone and that there is a large cavity to accept various N-substituted analogues of 10 such as risperidone and related agents. Alterations of this "extended" moiety improve receptor binding and functional potency. We propose a new risperidone-based pharmacophore for 5-HT receptor antagonist action.
5-HT 受体拮抗剂的药效基团模型由两个特定距离的芳香族/疏水区和一个碱性胺基组成。我们之前已经表明,对于结合或拮抗作用,这两个芳香族/疏水区都是不必要的。在这里,我们将 5-HT 受体拮抗剂/5-羟色胺多巴胺抗精神病药利培酮分解成更小的结构片段,以测试它们对 5-HT 受体的亲和力和功能。我们再次表明,整个利培酮结构对于保持亲和力或拮抗作用是不必要的。用等排色胺替代 6-氟-3-(4-哌啶基)-1,2-苯并[ d]异恶唑部分,保留了亲和力和拮抗作用。此外,仅包含利培酮一半结构特征的 3-(4-哌啶基)-1,2-苯并[ d]异恶唑(10),保留了两者的亲和力和拮抗作用。5-HT 受体同源建模/对接研究表明,10 以类似于利培酮的方式结合,并且存在一个大的空腔以接受各种 N-取代的 10 类似物,如利培酮和相关药物。该“扩展”部分的改变可提高受体结合和功能效力。我们提出了一种基于利培酮的新型 5-HT 受体拮抗剂药效基团模型。